Hydroxychloroquine use in the Baltimore Lupus Cohort: Effects on lipids, glucose and thrombosis

Lupus

Volumn 5, Issue SUPPL. 1, 1996, Pages

  Petri, M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetes mellitus; Hydroxychloroquine; Hyperlipidemia; Liver function tests; Thrombosis

Indexed keywords

ANTIMALARIAL AGENT; GLUCOSE; HYDROXYCHLOROQUINE; LIPID;

DIABETES MELLITUS; DRUG EFFICACY; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; LIVER FUNCTION TEST; PRIORITY JOURNAL; SHORT SURVEY; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; UNITED STATES;

EID: 0029990745     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203396005001051     Document Type: Short Survey

References (59)

1. Petri M, Howard D, Goldman DW. Side-effects of medications prescribed for systemic lupus erythematosus (abstract). Arthritis Rheum 1992; 35: S358.
2. Petri M, Perez-Gutthann S, Spence D, Hochberg MC. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 1992; 93: 513-519.
3. Petri M, Spence D, Bone LR, Hochberg MC. Coronary artery disease risk factors in the Hopkins Lupus Cohort: prevalence, patient recognition and preventive practices. Medicine 1992; 71: 291-302.
4. Petri M et al. Arterial thrombotic events (TE) in SLE: the Baltimore Lupus Cohort study (Abstract). Arthritis Rheum 1994; 37(Suppl. 9): S297.
5. Chen HW, Leonard DA. Chloroquine inhibits cyclization of squalene oxide to lanosterol in mammalian cells. J Biol Chem 1984; 259: 8156-8162.
6. Goldstein JL, Brown MS. The LDL pathway in human fibroblasts: a receptor-mediated mechanism for the regulation of cholesterol metabolism. Curr Top Cell Regul 1976; 11: 147-181.
7. Faust JR, Goldstein JL, Brown MS. Receptor-mediated uptake of low density lipoprotein and utilization of its cholesterol for steroid synthesis in cultured mouse adrenal cells. J Biol Chem 1977; 252: 4861-4871.
8. Oram JF, Albers JJ, Cheung MC, Bierman EL. The effects of subfractions of high density lipoprotein on cholesterol efflux from cultured flbroblasts. Regulation of low density lipoprotein receptor activity. J Biol Chem 1981; 256: 8348-8356.
9. Matsuzawa Y, Hosteller KY. Studies on drug-induced lipidosis: subcellular localization of phospholipid and cholesterol in the liver of rats treated with chloroquine of 4,4′-bis(diethylaminoethoxy) α,β-diehyldiphenylethane. J Lipid Res 1980; 21: 202-214.
10. Sewell RB, Barham SS, LaRusso NF. Effect of chloroquine on the form and function of hepatocyte lysosomes. Morphologic modifications and physiologic alterations related to the biliary excretion of Upids and proteins. Gastroenterology 1983; 85: 1146-1153.
11. LaFont H et al. Influence of acute injection of chloroquine on the biliary secretion of lipids and lysosomal enzyme in rats. Lipids 1984; 19: 195-201.
12. Lorber M et al. Hypocholesterolaemia and abnormal high-density lipoprotein in rheumatoid arthritis. Br J Rheumatol 1985; 24(3): 250-255.
13. Wallace DJ et al. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med 1990; 89: 322-326.
14. Hodis HN, Quismorio Jr FP, Wickham E, Blankenhom DH. The lipid, lipoprotein and apolipoprotein effects of hydroxychloroquine in patients with systemic lupus erythematosus J Rheumatol 1993; 20: 661-665.
15. Petri M, Lakatta C, Magder L, Goldman DW. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am J Med 1994; 96: 254-259.
16. Petri M et al. Dietary intervention for hypercholesterolemia in systemic lupus erythematosus (Abstract). Arthritis Rheum 1993; 36(9, Suppl.): S186.
17. Phillips RE et al. Hypoglycaemia and antimalarial drugs: quinidine and release of insulin. Br Med J (Clin Res Ed) 1986; 292(6531): 1319-1321.
18. Abu-Shakra M, Lee P. Hypoglycemia: an unusual adverse reaction to chloroquine (Letter). Clin Exp Rheumatol 1994; 12: 95.
19. Bamber MG, Redapth A. Chloroquine and hypoglycaemia (Letter). Lancet 1987; 1: 1211.
20. Smith GD, Amos TAS, Mahler R, Peters TJ. Effect of chloroquine on insulin and glucose homoeostasis in normal subjects and patients with noa-insulin-dependent diabetes mellitus. Br Med J 1987; 294: 465-467.
21. Blazer BR et al. In vivo chloroquine-induced inhibition of insulin degradation in a diabetic patient with severe insulin resistance. Diabetes 1984; 33: 1133-1136.
22. Khan MN et al. Insulin and insulin receptor uptake into rat liver. Chloroquine action on receptor recycling. Diabetes 1985; 34: 1025-1030.
23. Duckworth WC, Kitabchi AE. Insulin metabolism and degradation. Endocrine Rev 1981; 2: 210-233.
24. Neal GW, Kitabchi AE. Insulin degradation by human skeletal muscle. Biochim Biophys Acta 1982; 719: 259-266.
25. Dennis PA, Aronson Jr NN. The effects of low temperature and chloroquine on 1251-insulin degradation by the perfused rat liver. Arch Biochem Biophys 1981; 212: 170-176.
26. Fyles JM, Cawthorne MA, Howell SL. The effect of chloroquine on receptor internalization in pancreatic islets. Diabetic Med 1986; 3: P57, 373A.
27. Opara E, van Haeften T. Use of chloroquine in adipocyte insulin binding experiments: unproved estimation of insulin internalization and receptor bound insulin with linearization of the Scatchard plot (Abstract). Diabetes 1987; 26(Suppl. 1): 160A.
28. Cynober L et al. Modulation of insulin action on 2-deoxyglucose uptake by chloroquine in chick embryo flbroblasts. Diabetes 1987; 36: 27-32.
29. Fleig WE, Hoss G, Nother-Fleig G, Ditschuneit H. Insulin binding to cultured adult hepatocytes. Effects of bacitracin and chloroquine on the nature of cell-associated radioactivity. Biochem J 1986; 237: 99-104.
30. Sorimachi K, Okayasu T, Yasumura Y. Increase in insulin binding affinity by chloroquine in cultured rat hepatoma cells. Endocr Res 1987; 13: 49-60.
31. Quatraro A et al. Hydroxychloroquine in decompensated, treatment-refractory noninsulin-dependent diabetes mellitus. A new job for an old drug? Ann Intern Med 1990; 112(9): 678-681.
32. Petri M, Yoo S-S. Predictors of glucose intolerance in systemic lupus erythematosus (Abstract). Arthritis Rheum 1994; 37: S323.
33. Grafia J et al. Prospective study of 20 episodes of fever in 13 patients with systemic lupus erythematosus (Abstract). Arthritis Rheum 1994; 37(9, Suppl): S322.
34. Fries JF, Singh G, Lenert L, Furst DE. Aspirin, hydroxychloroquine and hepatic enzyme abnormalities with methotrexate in rheumatoid arthritis. Arthritis Rheum 1990; 33: 1611-1619.
35. Seideman P et al. Chloroquine reduces the bioavailability of methotrexate in patients with rheumatoid arthritis. A possible mechanism of reduced hepatotoxicity. Arthritis Rheum 1994; 37(6): 830-833.
36. Petri M, Baker C, Goldman D. Liver function test (LFT) abnormalities in systemic lupus erythematosus (SLE) (Abstract). Arthritis Rheum 1992; 35: S239.
37. Loudon JR. Hydroxychloroquine and postoperative thromboembolism after total hip replacement. Am J Med 1988; 85(Suppl. 4A): 57-61.
38. Johnson R, Loudon JR. Hydroxychloroquine sulfate prophylaxis for pulmonary embolism for patients with low-friction arthroplasty. Clin Orthop 1986; 211: 151-153.
39. Johnson R, Charnley J. Hydroxychloroquine in prophylaxis of pulmonary embolism following hip arthroplasty. Clin Orthoped 1979; 144: 174-177.
40. Carter AE, Eban R, Perrett RD. Prevention of post-operative deep venous thrombosis and pulmonary embolism. Br Med J 1971; 1: 312-314.
41. Carter AE, Eban R. Prevention of postoperative deep venous thrombosis in legs by orally administered hydroxychloroquine sulfate. Br Med J 1974; 3: 94-95.
42. Pilcher DB. Hydroxychloroquine sulfate in prevention of thromboembolic phenomena in surgical patients. Am Surgeon 1975; 41: 761-766.
43. Hansen EH et al. Hydroxychloroquine sulphate in prevention of deep venous thrombosis following fracture of the hip, pelvis or thoracolumbar spine. J Bone Jt Surg 1976; 58A: 1089-1093.
44. Chrisman DO, Snook GA, Wilson TC, Short JY. Prevention of venous thromboembolism by administration of hydroxychloroquine. J Bone Jt Surg 1976; 58A: 918-920.
45. Cook ED et al. Failure of orally administered hydroxychloroquine sulphate to prevent venous thromboembolism following elective hip operations. J Bone Jt Surg 1977; 59A: 496-500.
46. Johansson E, Forsberg K, Johnsson H. Clinical and experimental evaluation of the thromboprophylactic effect of hydroxychloroquine sulfate after total hip replacement. Haemostasia 1981; 10: 89-96.
47. Wu TK, Tsapogas MJ, Jordan FR. Prophylaxis of deep venous thrombosis by hydroxychloroquine sulfate and heparin. Surg Gynecol Obstet 1977; 145: 714-718.
48. Winocour PD, Kinlough-Rathbone RL, Mustard JF. The effect of the phospholipase inhibitor mepacrine on platelet aggregation, the platelet release reaction and fibrinogen binding to the platelet surface. Thrombosis Haemostasis 1981; 45: 257-262.
49. Seuter F. Inhibition of platelet aggregation by acetylsalicylic acid and other inhibitors. Haemostatis 1976; 5: 85-95.
50. Rosenberg FJ et al. Acetylsalicylic acid: inhibition of platelet aggregation in the rabbit. J Pharm Exp Ther 1971; 179: 410-418.
51. Madow BP. Use of anti-malarial drugs as 'desludging' agents in vascular disease processes. JAMA 1960; 172: 1630-1633.
52. Knisely MH, Strathman-Thomas WK, Elliot TS. Capillary circulation in malarial infected monkey: gnematographic study. JAMA 1941; 116: 2430-2431.
53. Cecchi E, Ferraris D. Desludging action of hydroxychloroquine in rheumatoid arthritis. Acta Rheumatol Scand 1962; 8: 214-221.
54. Ernst E, Rose M, Lee R. Modification of trans-operative changes in blood fluidity by hydroxy-chloroquine. A possible explanation for the drugs anti-thrombotic effect. Pharmatherapeutica 1984; 4: 48-52.
55. Bird HA, Harkness J, Wright V. Some Theological properties of blood during anti-rheumatoid therapy. Pharmatherapeutica 1981; 3: 36-39.
56. Rosenberg FJ, Phillips PG, Druzba PG. Platelets and thrombosis. Use of a rabbit extracarporeal shunt in the assay of antithrombotic and thrombotic drugs. Baltimore University Park Press 1974: 233-234.
57. Wallace D. Does hydroxycbloroquine sulfate prevent clot formation in systemic lupus erythematosus? (Letter). Arthritis Rheum 1987; 30: 1435-1436.
58. Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991; 324: 150-154.
59. Kruize AA et al. Hydroxychloroquine treatment for primary Sjogren's syndrome: a two year double blind crossover trial. Ann Rheum Dis 1993; 52(5): 360-364.